Synlogic (SYBX) Tops Q4 EPS by 7c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 12, 2019 7:00 AM EDTEnded 2018 with approximately $123 million in cash and investments, which provides runway through 2020
Clinical trial readouts expected in mid-2019 from two Synthetic Biotic medicines and first IND application expected from Synlogics immuno-oncology platform in second half of 2019
Company will host a conference call and webcast at 8:00 am ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Synlogic, Inc.... More



